anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our objective was to determine the effects of nondigestible oligosaccharides (NDO) on lung health and performance. Three hundred male Holstein-Friesian calves aged 18.0 ± 3.6 d received 1 of 6 treatments for 8.5 wk (period 1). Treatments included a negative control (CON), galacto-oligosaccharides (GOS) administered as a spray via the nose once daily (SPR), GOS administered via the milk replacer (MR) at 1% (GOS-L) and 2% (GOS-H), fructo-oligosaccharides administered via the MR at 0.25% (FOS) and a combination of GOS and fructo-oligosaccharides administered via the MR at 1% and 0.25%, respectively (GOS-FOS). Milk replacer was fed twice daily. Feeding levels were equal between calves and increased progressively in time. Body weight was measured every 4 wk and clinical health was scored weekly. Blood and broncho-alveolar lavage fluid (BALF) samples were collected bi-weekly from a subset of calves (n = 120). After period 1, all calves received the same control MR for 18 wk until slaughter (period 2), during which general performance and clinical health were measured. Generally, infection pressure was high, with clinical scores and BALF proinflammatory TNFα concentrations increasing with time in period 1, which resulted in a high number of required group antimicrobial treatments (6 group antimicrobial treatments in 13 wk, supplied to all calves). Average daily gain adjusted to equal solid feed intake was increased for GOS-L (+61 g/d) compared with CON calves from experimental wk 1 to 5. Plasma white blood cell concentration tended to be lowered by GOS-L, plasma IL-8 concentration was reduced by all orally supplemented NDO, plasma IL-6 was reduced by all NDO treatments except GOS-FOS and plasma IL-1β was reduced by all NDO treatments compared with CON, although this differed per time point for SPR. The neutrophil percentage in BALF was reduced by GOS-L in wk 6, which was associated with a relative increase in macrophages. The BALF concentration of TNFα and IL-8 was reduced or tended to be reduced by GOS-L and GOS-H, while IL-6 was or tended to be reduced by SPR, GOS-L, GOS-H, and GOS-FOS, and IL-1β was reduced by SPR, GOS-L, GOS-H, and FOS. Generally, feeding the combination of GOS and FOS was not more effective than feeding GOS or FOS alone, because feeding GOS-FOS resulted in higher concentrations of plasma and BALF cytokine and chemokine concentrations compared with feeding GOS-L alone, and resulted in higher plasma cytokine concentrations compared with feeding FOS alone. None of the BALF and plasma cytokine or chemokine concentrations differed between the GOS-L and GOS-H treatment. Performance and clinical scores in period 2 did not differ among treatments. Altogether, all tested NDO reduced systemic and lung inflammation in calves under high natural infection pressure and for GOS-fed calves, this increased performance during the first 4 wk. Combining GOS and FOS did not have a synergistic effect. The intranasal administration of GOS also lowered systemic and lung inflammation, but tended to negatively affect performance. Overall, this study demonstrates the potential of NDO to alleviate systemic and respiratory inflammation in calves.
BACKGROUND: Neonatal cardiac tumors are a rare pathology, with an approximate incidence of 0.017% in autopsies and 0.31% in obstetric echographies. The most common primary cardiac tumor is rhabdomyomas and its clinical manifestations are highly variable. Most patients do not require therapeutic management unless there is hemodynamic compromise, in which one option is surgical management, which implies high mortality. Rhabdomyomas are usually associated with tuberous sclerosis, a disease for which drugs such as everolimus or sirolimus have been used.
CLINICAL CASE: Newborn male patient with no significant history, in whom a cardiac arrhythmia was detected during the routine physical examination. After the evaluation by Pediatric Cardiology, it was determined that the patient had supraventricular extrasystoles, in addition to multiple intracardiac masses that, due to imaging characteristics, were compatible with rhabdomyomas, so it was determined that the cause of cardiac arrhythmia was the presence of multiple tumors. Due to the condition of the conduction system, everolimus and propranolol were used. After 7 days, control of the arrhythmias was achieved and resolution of the tumors was achieved after 8 weeks.
CONCLUSIONS: Rhabdomyomas are cardiac tumors associated with tuberous sclerosis, clinical complications can be managed effectively with everolimus as in the case presented.
Cardiovascular disease (CVD) is one of the leading causes of mortality worldwide, and multiple single‑nucleotide polymorphisms of DNA repair genes have been found to be associated with CVD. The aim of the present study was to assess the effects of the genetic variants of RAD51 recombinase (RAD51) and 8‑oxoguanine DNA glycosylase (OGG1) on CVD through genotyping and statistical analysis. Regardless of whether there is a significant association or not, the genotyping data on these two polymorphisms are valuable, because there is limited availability of it in certain populations. A total of 240 blood samples were analyzed and genotyped using TaqMan genotyping; 120 were obtained from cases with a history of CVD, and 120 from cases with no history of CVD. A questionnaire was administered to gather information on age, demographics, sex and clinical features, and confirmation was carried out using medical records. The results of the present study confirmed that the polymorphism rs1052133 in OGG1 had no significant association with CVD. On the other hand, the polymorphism rs1801321 in RAD51 exhibited a significant association with CVD. Collectively, the results of the present study revealed that the polymorphism rs1801321 in RAD51 exhibited a significant association with CVD, however a larger sample size to confirm the present findings, may allow for the early identification of CVD and may aid in the decision‑making process concerning treatments for CVD.
Xenologous nucleic acids (i.e. those obtained from animal species other than that of the receiver) are used to treat a transplantate after removal from the donor and before implantation, thus increasing the survival time of the transplantate. The nucleic acid is pref. obtained from mammal foetuses by phenol extraction and is used in the form of a soln. in a physiologically compatible vehicle, pref. saline, pref. with a substance to increase penetration into the tissue, esp. protamine or diethylaminoethanol.
Patients receive CA-4948 PO BID on days 1-14 of each cycle, bevacizumab IV over 30-90 minutes on day 1 of each cycle beginning in cycle 2, and oxaliplatin IV over 120 minutes, leucovorin IV over 2 hours, and fluorouracil IV bolus followed by continuous IV infusion over 46 hours on day 1 of each cycle. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity. After treatment for 2 years, patients may continue treatment after discussion with the study chair. Patients also undergo blood sample collection and CT, MRI, or PET/CT throughout the trial. Patients also undergo tumor biopsy throughout the trial.
PCT No. PCT/US95/04071 Sec. 371 Date Sep. 16, 1996 Sec. 102(e) Date Sep. 16, 1996 PCT Filed Mar. 30, 1995 PCT Pub. No. WO95/26718 PCT Pub. Date Oct. 12, 1995Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a genetic vaccine facilitator and administering to the cells a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.
The RPNI procedure involves construction of a residual peripheral nerve split into several nerve fascicles and implanted into free skeletal muscle grafts. First, the surgeon identifies the nerve with a painful neuroma and resect the neuroma up to healthy fascicles. Then, a longitudinal intraneural dissection will be performed exposing its fascicles. Next, autologous muscle grafts will be harvested from a healthy donor site, and the dissected nerve stumps will be placed parallel to the muscle fibers. The nerve stump will be secured to the muscle graft, thereafter the graft will be wrapped around the nerve stump and anchored in the folded graft, thus creating an RPNI. This will be repeated for each fascicle obtained from splitting the transected nerve. Lastly, the RPNIs will be placed in a protected area. The surgery time is approximately 2-3 hours and it takes place in the hospital.
Individuals with a history of moderate to severe TBI experience multi-faceted sleep problems, including greater daytime sleepiness, lesser total sleep time, and difficulties with initiating, maintaining, and self-monitoring sleep. Such sleep complaints may reflect underlying sleep conditions such as insomnia, the prevalence of which is significantly greater among individuals with TBI (29%) compared to members of the general population (10%). As such, treatment of insomnia among individuals with moderate to severe TBI is expected to produce wide-ranging benefits in regards to short- and long-term rehabilitation. Among members of the general population, cognitive behavioral therapy for insomnia (CBT-I) is considered the gold standard for treating insomnia. CBT-I focuses on improving sleep quality via cognitive therapy, behavioral techniques, and psychoeducation. However, access to in-person treatment has been limited by cost, insufficient numbers of adequately trained healthcare providers, and patient perceptions regarding the efficacy of the intervention, as well as additional barriers that may be particularly pertinent for those living with moderate to severe TBI (e.g., limited transportation). Optimally, an intervention for those with TBI and insomnia would show efficacy at reversing sleep inefficiency, and be able to be used with minimal stigma. In addition, the intervention should be highly accessible, low cost, self-sustaining (e.g., portable), and with minimal side effects.

Computerized versions of CBT-I assist in reducing barriers to access and have been found to be acceptable and efficacious in a variety of populations, including those with mild TBI. To date, research among those with moderate to severe TBI has been limited. This study will address this gap by examining the efficacy of a guided computerized CBT-I (CCBT-I) intervention for those with moderate to severe TBI and insomnia. That is, we will implement a free, computerized version of CBT-I, provided in conjunction with guidance (e.g., prompts or reminders to complete modules, help or support using the program and/or completing the modules) by a licensed mental health professional (Study Clinician). As participants will be recruited from the community at-large across the State of Colorado, it is believed that findings will be highly generalizable.

Moreover, both geography (where an individual resides) and challenges with transportation create barriers to treatment access and research participation among those living with moderate to severe TBI. As such, all study procedures will be completed remotely. During the Coronavirus Disease 2019 (COVID-19) pandemic, members of this study team explored and implemented multiple methods to facilitate remote research participation (e.g., video conferencing, data collection via Research Electronic Data Capture \[REDCap\], mailing study data collection devices). Employing such methods will allow individuals in both rural and urban areas across Colorado to participate.
VERMOX™ CHEWABLE (mebendazole chewable tablets) is an orally administered anthelmintic. Chemically, it is methyl 5-benzoylbenzimidazole-2-carbamate. Its molecular formula is C16H13N3O3. Its molecular weight is 295.30. It has the following chemical structure:

Mebendazole exhibits polymorphism. The polymorph used in VERMOX™ CHEWABLE is polymorph form C. Mebendazole is a white to almost white powder. It is practically insoluble in water, in ethanol (96%) and in methylene chloride.

Each round, flat radius-edged white to yellowish chewable tablet contains 500 mg of mebendazole and is debossed with "M/500" on one side and "J" on the other side.

Inactive ingredients consist of: crospovidone, magnesium stearate, microcrystalline cellulose, povidone, purified water, strawberry flavor and sucralose.
PROBLEM TO BE SOLVED: To correctly manage patients by printing and reading a two-dimensional code including information such as the ID number, birth date, name and insurance king, etc., of a patient coded on a consultation ticket. SOLUTION: On this consultation ticket 11, the ID number 12, the birth date 13, the insurance kind 14 and the name 15 of a patient are entered. Also, on the lower side of the name 15, a two-dimensional code 16, on which information such as the name, the ID number, the birth date, the insurance kind and the image data of an insurance policy, etc., is made into the two-dimensional code, is printed. The consultation ticket 16 is read by a two-dimensional code reader and the ID number, the birth date, the insurance kind and the name in the two-dimensional code are displayed at a display part together with the image date of the insurance policy. Also, the patient information such as the name, the ID number and the birth date, etc., in the two-dimensional code is compared with the patient information such as the name, the ID number and the birth date, etc., stored in a RAM. Then, in the case of judging that they do not match, the patient information stored in the RAM is updated.
Opioid administration guided by Pain Pupillary Index (PPI) derived from Videopupillometry performed with the device AlgiScan manufactured by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following an electric nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 milliampere depending on the degree of PRD and afterwards displays the PPI. The numerical index ranges from 0 to 10. A low PPI score indicates a deep analgesia, a high PPI score indicates an insufficient or light analgesia. A PPI score of 2 or 3 is supposed to represent an optimal level of analgesia according to the manufacturer. 5 µg sufentanil will be administered every 5 minutes if PPI score is calculated more than 3.
<P>PROBLEM TO BE SOLVED: To obtain an anti-Helicobacter pylori agent containing an extract of Mekabu (fertile leaf separated from a stem of seaweed) and an extract of alga belonging to the genus Ascophyllum and a food and beverage containing the same.  <P>SOLUTION: The anti-Helicobacter pylori agent contains an extract of Mekabu (fertile leaf separated from a stem of seaweed) and an extract of alga belonging to the genus Ascophyllum. The extract of Mekabu (fertile leaf separated from a stem of seaweed) is preferably obtained by extraction with an aqueous solvent and the extract of an algae belonging to the genus Ascophyllum is preferably obtained by extraction with an aqueous solvent. The extract of Mekabu (fertile leaf separated from a stem of seaweed) and the extract of alga belonging to the genus Ascophyllum are preferably a mixed extract obtained by extraction from a mixture comprising Mekabu (fertile leaf separated from a stem of seaweed) and an alga belonging to the genus Ascophyllum. Especially, the mixed extract is preferably obtained by extraction from a mixture containing 5-50 mass% of Mekabu (fertile leaf separated from a stem of seaweed). The food and beverage contains the anti-Helicobacter pylori agent. The food and beverage contains preferably 0.001-20 mass% of the mass of the total of the extract of Mekabu (fertile leaf separated from a stem of seaweed) and the extract of alga belonging to the genus Ascophyllum.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The aim of this review is to provide an overview of per-oral endoscopic myotomy (POEM) and its utilization in non-achalasia disorders of the esophagus. POEM, a relatively novel endoscopic technique, involves submucosal tunneling to access esophageal muscle layers, enabling selective myotomy and mitigating the consequences of motor disorders of the esophagus. POEM is an effective treatment modality for diffuse esophageal spasm providing resolution of chest pain and dysphagia in a majority of patients who have refractory symptoms despite medical therapy. The results of POEM are more equivocal compared to esophagogastric junction outflow obstruction (EGJOO). POEM in EGJOO has been shown to have a 93% clinical success rate in 6 months. POEM appears to be more effective in motor disorders that affect the lower esophageal sphincter, such as EGJOO and opioid-induced esophageal dysfunction. While the current data for POEM in other entities such as DES and HE are positive, more supportive data are required to make POEM a consistent recommendation for patients.
PCT No. PCT/JP96/01815 Sec. 371 Date Feb. 27, 1997 Sec. 102(e) Date Feb. 27, 1997 PCT Filed Jul. 1, 1996 PCT Pub. No. WO97/01356 PCT Pub. Date Jan. 16, 1997A cholesterol ester clathrate comprising a cholesterol ester included within a hydroxyalkylated cyclodextrin; a hydrous composition comprising a hydroxyalkylated cyclodextrin, a cholesterol ester and water; a hydrous composition comprising a hydroxyalkylated cyclodextrin, a cholesterol ester, a hydrous stabilizer, and water; a hydrous composition comprising a hydroxyalkylated cyclodextrin, a cholesterol ester, a clay mineral, and water; a cosmetic containing a hydrous composition; and processes for making the cholesterol ester clathrate and various hydrous compositions. The cholesterol ester clathrate exhibits an emulsifying effect and the hydrous compositions are excellent in water-holding capacity, hydration properties, and separation stability at a high temperature.
The invention discloses a compound synsepalum dulcificum leaf extract. The compound synsepalum dulcificum leaf extract is prepared from Chinese herbal medicine raw materials, the main material is synsepalum dulcificum leaf, and the auxiliary material is a combination of any three of radix paeoniae rubra, tribulus terrestris, astragalus, rhodiola rosea and scutellaria baicalensis. The invention also discloses a preparation method of the compound synsepalum dulcificum leaf extract. The method includes: preparation of Chinese herbal medicine raw materials, pretreatment, extraction, rough filtration, fine filtration, concentration, re-dissolution and sterilization. The invention also discloses application of the compound synsepalum dulcificum leaf extract in cosmetics with anti-aging efficacy. The compound synsepalum dulcificum leaf extract provided by the invention has antioxidant activity and tyrosinase inhibitory activity, makes up the drawback that synsepalum dulcificum leaf only has strong antioxidant activity, and can be applied as an anti-aging functional component in cosmetics.
The present invention relates to methods for improving the viability and recovery of islets that are separated from a donor organ for subsequent transplantation. In a preferred embodiment, the islets are separated from a donor pancreas and transplanted into the liver of a diabetic patient. One or more emulsified perfluorocarbons (ePFCs) may be infused into the donor pancreas prior to islet isolation and transplantation. The ePFCs may enhance the oxygenation of islets, thereby enhancing their viability and health so they may withstand a vigorous isolation procedure such as the Edmonton Protocol. The present invention not only preserves the donor organ using ePFC, but also rescues islets and donor organs that would otherwise be damaged or destroyed during isolation and transplantation procedures. The separated islets may be injected into the portal vein of a liver where they will assist in producing insulin and regulating blood glucose levels.
AIMS: The objective of this study was to identify the presence of human herpesvirus (HHV) in the plasma and saliva of hepatic-cirrhosis patients and correlate it with clinical data and laboratory tests. This is a pilot, observational, and cross-sectional study.
METHODS AND RESULTS: Specimens of plasma and saliva from 72 cirrhotic individuals were analyzed by means of polymerase chain reaction. The patient population had a mean age of 54.84 years old (SD ± 10) and was 70% males (51/72). Approximately 47% (n = 34) of the patients had leukopenia and HHV was not identified in the plasma specimens. The main species of HHV identified in the saliva were HHV-7 (n = 42, 62%) and Epstein-Barr virus (EBV) (n = 30, 41%). Moreover, there was a significant decrease in the total number of leukocytes and lymphocytes in saliva containing EBV (P = .038 and P = .047, respectively).
CONCLUSION: The results show that the presence of EBV in the saliva of cirrhotic patients was correlated with their circulating immune status. It may be possible that the immune dysfunction displayed by the cirrhotic patients plays a role in the shedding of EBV into saliva.
Acute esophageal necrosis (AEN), also known as Gurvits syndrome, is a rare and potentially life-threatening condition characterized by necrosis of the esophageal mucosa. Acute esophageal necrosis is often associated with critical conditions, such as myocardial infarction, diabetic ketoacidosis (DKA), coronavirus disease 2019 (COVID-19) infection, or post-surgical complications. Patients typically present with nausea, hematemesis, acute dysphagia, and melena. Given its high mortality rate, prompt detection with upper endoscopy and early initiation of treatment are crucial. Most cases of Gurvits syndrome are managed conservatively using intravenous fluids, proton pump inhibitors, and antibiotics. Herein, we present a case series of AEN in the setting of DKA. Both patients received supportive care and were discharged in a stable condition.
PURPOSE: A composition for anticancer containing marine microorganism extract is provided to suppress penetration and proliferation of cancer and induce apoptosis. CONSTITUTION: A composition for anticancer contains Pseudomonas sp. extract as an active ingredient. The cancer is head and neck cancer, oral cancer, colorectal cancer, stomach cancer and liver cancer. The Pseudomonas sp. is Pseudoalteromonas sp.(KCTC11358BP). The mechanism of anticancer is performed through apoptosis or necrosis.
PURPOSE:To enable examinations and diagnoses of a variety of diseases to be accomplished by using as antigen a polypeptide of the amino acid sequence corresponding to gene of retrovirus. CONSTITUTION:A polypeptide with homology between retrovirus is synthesized by solid phase process to obtain (A) a synthetic polypeptide of formula I, II or III (abbreviations such as LEL are amino acid of formula IV). Thence, the component A is injected into mice to effect immunization, thus producing (B) cells, hybridoma, of SP-2 SO1-1F, SP-2 SO2-11G or SP-2 SO3-A7. The cells B are then put to culture in a medium containing e.g. fetal bovine serum and the resultant cultured product is purified to produce (C) monoclonal antibody with, as antigen, a polypeptide of the amino acid sequence of formula V, VI or VII for SO1, SO2 or SO3, respectively. If needed, this antibody is subjected to antigen-antibody reaction with unknown pathogenic retrovirus to detect pathogenic retrovirus.